Cadence Partners With Antiviral Discovery Consortium To Spearhead Rapid Development Of Treatments For Viral Pandemics; Antiviral Discovery Effort Funded By $68M NIH Grant
Portfolio Pulse from Benzinga Newsdesk
Cadence Design Systems' business unit, Cadence Molecular Sciences (OpenEye), is partnering with the ASAP Discovery Consortium to develop antivirals for pandemics, supported by a $68M NIH grant. OpenEye will provide molecular design software to aid in drug discovery. The consortium, led by John D. Chodera of MSKCC, aims to deliver drug candidates ready for human evaluation in case of pandemic threats, using an open science model for equitable access. The project builds on the COVID Moonshot initiative's success.
December 07, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cadence Design Systems, through its OpenEye unit, is contributing software tools to the ASAP Discovery Consortium for antiviral drug development, funded by a $68M NIH grant.
The partnership with the ASAP Discovery Consortium and the NIH grant highlight Cadence's involvement in significant public health efforts. This positive exposure and potential future opportunities in the healthcare sector could lead to increased investor interest and a positive short-term impact on CDNS stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80